Last reviewed · How we verify
MLC601
MLC601, developed by Shahid Beheshti University, is a marketed drug with an unknown mechanism of action. The key composition patent for MLC601 is set to expire in 2028, which may provide a period of market exclusivity. The primary risk is the lack of a defined mechanism of action, which could limit its adoption and regulatory support.
At a glance
| Generic name | MLC601 |
|---|---|
| Also known as | NeuroAid |
| Sponsor | Shahid Beheshti University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Spinal Cord Injury - Assessing Tolerability and Use of Combined Rehabilitation and NeuroAiD (PHASE4)
- NeuroAiD Safe Treatment Registry
- The Alzheimer's Disease THErapy With NEuroaid (ATHENE) Study (PHASE2)
- Efficacy and Tolerability of MLC601 in Patients With Mild to Moderate Alzheimer Disease Who Were Unable to Tolerate or Failed to Benefit From Treatment With Rivastigmine (PHASE2)
- Clinical Study to Investigate the Safety and Efficacy of MLC601 in 150 Iranian Patients After Stroke (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |